相关临床试验
1793
164 进行中
药物批准
4
批准总数
监管机构
1
监管机构数
成立时间
1891
Unknown
15
0.8%
已完成
1028
57.3%
Enrolling By Invitation
16
0.9%
尚未招募
37
2.1%
No Longer Available
2
0.1%
终止
252
14.1%
招募中
219
12.2%
暂停
6
0.3%
Approved For Marketing
1
0.1%
撤回
106
5.9%
进行中（未招募）
111
6.2%
- A 69-year-old woman's persistent abdominal bloating was ultimately diagnosed as Stage 4 ovarian cancer after a nurse practitioner ordered a CT scan instead of the expected colonoscopy. - Oncologist Dr. Premal Thaker of Washington University School of Medicine describes ovarian cancer as "very insidious," with subtle symptoms that mimic menopause or milder conditions. - Patients with Stage 4 ovarian cancer have roughly a 30% five-year survival chance, and about 70% of patients will see their disease return, according to cited organizations. - The patient's treatment combined neoadjuvant chemotherapy, February 2025 surgery including hysterectomy, resumed chemotherapy, immunotherapy infusions, and an ongoing daily chemotherapy pill.
- A prospective multicenter analysis of 787 brain tumor patients found that the extent of tumor ablation and timing of laser interstitial thermal therapy (LITT) significantly influence survival outcomes. - Glioblastoma patients with at least 91% of their tumor cleared by the laser survived 2.1 years from diagnosis, compared with roughly 1.5 years for standard open surgical resection. - The minimally invasive NeuroBlate procedure requires only a single-stitch incision, limits average hospital stay to 32 hours, and preserves day-to-day quality of life. - Researchers suggest the laser therapy may be considered up front for newly diagnosed glioblastoma and earlier for small brain metastases rather than watchful waiting.
- Researchers at Washington University School of Medicine discovered that ETEC and Shigella rely on three closely related enzymes — EatA, SepA, and Pic — to penetrate the gut's protective mucus layer and cause infection. - Antibodies targeting a shared region of these enzymes were shown to neutralize all three, blocking the bacteria from breaching the intestinal mucus barrier, based on samples from infected patients and controlled human challenge studies. - Cryo-electron microscopy performed at the University of Missouri pinpointed the precise binding site of the most effective neutralizing antibodies, establishing a foundation for rational vaccine design. - The findings, published June 15 in PNAS, suggest a single combination vaccine could protect against multiple major causes of severe diarrhea, addressing a long-standing unmet need for children in endemic regions and travelers worldwide.
- A new study in Nature Medicine links faster biological aging in younger generations to increased risk of early-onset solid cancers, including lung, gastrointestinal, and uterine cancers. - UK Biobank data shows participants born between 1965 and 1974 had larger age gaps than those born between 1950 and 1954 at the same chronological ages. - Those in the highest biological aging group had a roughly 15% higher risk of early-onset solid cancer compared to the lowest group, though causality remains unproven. - Researchers emphasize the findings are proof-of-concept and require validation, as biological aging clocks like PhenoAge need further refinement for cancer risk assessment.
- Researchers at Washington University School of Medicine achieved the first successful genetic modification of human hookworms using CRISPR/Cas9, reported in Nature Communications. - Engineered hookworms produced an antibody neutralizing tetrodotoxin and secreted it into the bloodstream of infected hamsters, achieving approximately 20% toxin neutralization. - The proof-of-concept study demonstrates a potential long-term drug delivery platform for chronic conditions including inflammatory bowel diseases, allergies, and obesity. - Future development requires optimization of therapeutic output, multi-generational gene stability, and rigorous safety evaluations including biocontainment strategies before human testing.
- The FDA has approved InspireMD's Investigational Device Exemption application to initiate the CGUARDIANS III pivotal study of its SwitchGuard neuro protection system for stroke prevention. - The study will evaluate next-generation enhancements to the SwitchGuard system for use with the CGuard Prime 80 cm stent platform in transcarotid artery revascularization procedures. - InspireMD targets a U.S. commercial launch of the SwitchGuard NPS in 2027, pending regulatory approval following successful completion of the pivotal trial. - The study will be led by the same investigators who conducted the previous CGUARDIANS II trial, ensuring continuity in clinical development.
- A major NIH-sponsored clinical trial involving 225 patients across 29 U.S. sites demonstrated that stent placement significantly reduces post-thrombotic syndrome severity from 93% to 40% of patients meeting severe criteria. - The minimally invasive procedure, which takes two to three hours and requires only tiny incisions, improved quality of life scores by 14 points on a 100-point scale compared to standard care alone. - This represents the first large randomized trial to provide evidence-based treatment for post-thrombotic syndrome, a painful complication affecting an estimated 40% of deep vein thrombosis survivors. - The C-TRACT trial results, published in the New England Journal of Medicine, offer new hope for over 120,000 Americans annually who develop this debilitating condition following blood clots.
- Researchers at Washington University School of Medicine and Weizmann Institute of Science have successfully adapted CAR-T cell therapy, originally developed for cancer treatment, to target Alzheimer's disease in mice. - The engineered CAR-T cells specifically targeted amyloid beta plaques in the brain, resulting in significant plaque reduction and decreased brain inflammation compared to control treatments. - This represents the first application of CAR-T cell therapy for neurodegenerative diseases and could potentially be adapted for other conditions including ALS and Parkinson's disease. - The study demonstrates improved brain health in treated mice, with reduced activation of microglia and astrocytes following plaque reduction.
- Researchers at Washington University School of Medicine developed a nasal spray vaccine for H5N1 bird flu that provided near-complete protection against infection in hamsters and mice. - The nasal vaccine generated stronger immune responses and better protection than traditional intramuscular vaccines, particularly in preventing infection in the nose and lungs where flu viruses first establish themselves. - The vaccine remained effective even in animals with pre-existing immunity from prior flu exposure, addressing a key concern for practical deployment. - With over 70 human H5N1 cases in the US since 2022 and the virus spreading to dairy cattle, scientists warn of increasing pandemic potential as the virus gains more opportunities to mutate.
- Researchers at Washington University School of Medicine developed a bispecific T cell engager (BiTE) immunotherapy that significantly reduced atherosclerotic plaque in mouse models of coronary artery disease. - The therapy targets modulated smooth muscle cells expressing fibroblast activation protein, which drive inflammation and dangerous plaque formation in arterial walls. - Single-cell analysis of 27 human coronary arteries identified these harmful cells in plaque-vulnerable areas, with PET/CT imaging successfully detecting them in patients with coronary artery disease. - The treatment could complement existing cholesterol-lowering therapies by addressing established plaques that remain despite optimal medical management.
